Archive · 16 Jan 2026
Sun Pharma Launches Skin Cancer Drug in US
Sun Pharma, a big Indian medicine company, has started selling a new drug called Unloxcyt in the US.
This drug is for people with a serious type of skin cancer called cutaneous squamous cell carcinoma.
It's for patients who can't have surgery or radiation to cure the cancer.
The drug is available through special pharmacies in the US.
Sun Pharma is a major supplier of generic medicines worldwide, and this new drug is an important addition to their products.
The company's shares were a bit lower on the day they announced this news.
Sun Pharmaceutical Industries launched Unloxcyt (cosibelimab-ipdl) in the US for treating metastatic or locally advanced cutaneous squamous cell carcinoma.
The drug is available through a limited distribution network of authorized speciality distributors and one contracted speciality pharmacy.
Unloxcyt is designed for adults who are not candidates for curative surgery or radiation.
Cutaneous squamous cell carcinoma is a common skin cancer, with an estimated 40,000 US patients progressing to advanced disease annually.
Sun Pharma shares were trading 2.2% down at ₹1,663.20 apiece on BSE.
- Who
- Sun Pharmaceutical Industries
- What
- Launched skin cancer drug Unloxcyt in the US
- When
- January 16, 2026
- Where
- United States
- Why
- To treat adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation
- Drug Name
- Unloxcyt (cosibelimab-ipdl)
- Indication
- Metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC/llaCSCC)
- Availability
- US market
- Distribution
- Limited distribution network of authorized speciality distributors and one contracted speciality pharmacy
- Company
- Sun Pharmaceutical Industries
- CEO
- Richard Ascroft
- Stock Price
- ₹1,663.20 (down 2.2%)